Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cardiol Therapeutics Inc T.CRDL

Alternate Symbol(s):  CRDL

Cardiol Therapeutics Inc. is a clinical-stage life sciences company. The Company is focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. Its lead drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It is recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with myocarditis, pericarditis, and heart failure. It is also developing CRD-38, a novel subcutaneously administered drug intended for use in heart failure. It has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart.


TSX:CRDL - Post by User

Bullboard Posts
Comment by TechnicallyHighon Feb 15, 2019 10:45am
43 Views
Post# 29370435

RE:I think Cardiol Therapeutics is heading to $20.00 per share

RE:I think Cardiol Therapeutics is heading to $20.00 per shareVery promotional post... but at least Im on your side. 

CRDL needs to get into the US biotech investor group. They will recognize this as a company who has vertically integrated its main ingredient. While it gets its drug's approved, it has a retial product.. 

1 million grams = 100 million in top line revenue that will be in inventory by Q4/19. MSRP is $100/g if you sell BELOW others (Aphria is like $150/gram) ..You cant even get 80% pure CBD on any major Canadian distribution points.. 

And think about them selling their water soluble products..

If Canapy, Aphria, Novartis, etc etc are smart, they scoop this up before the it gets to $20. 

Bullboard Posts